About Shattuck Labs
Shattuck Labs is a company based in Austin (United States) founded in 2016. Shattuck Labs has raised $165.4 million across 7 funding rounds from investors including Fidelity Investments, Orbimed and Janus Henderson Investors. The company has 44 employees as of December 31, 2024. Shattuck Labs offers products and services including SL-325. Shattuck Labs operates in a competitive market with competitors including ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
- Headquarter Austin, United States
- Employees 44 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Shattuck Labs, Inc.
-
Annual Revenue
$5.72 M (USD)245.26as on Dec 31, 2024
-
Net Profit
-$75.41 M (USD)13.62as on Dec 31, 2024
-
EBITDA
-$76.52 M (USD)12.97as on Dec 31, 2024
-
Total Equity Funding
$165.4 M (USD)
in 7 rounds
-
Latest Funding Round
$103 M (USD), Post-IPO
Aug 26, 2025
-
Investors
Fidelity Investments
& 9 more
-
Employee Count
44
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Shattuck Labs
Shattuck Labs is a publicly listed company on the NASDAQ with ticker symbol STTK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Shattuck Labs
Shattuck Labs offers a comprehensive portfolio of products and services, including SL-325.
Antagonist for Death Receptor 3 to block TL1A pathway in autoimmune diseases.
People of Shattuck Labs
Unlock access to complete
Unlock access to complete
Funding Insights of Shattuck Labs
Shattuck Labs has successfully raised a total of $165.4M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $103 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Shattuck Labs
Shattuck Labs has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Orbimed and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe
|
Locked | Locked | Locked | |
|
Healthcare companies are invested in by this private equity firm.
|
Locked | Locked | Locked |
Investor details for Shattuck Labs
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Shattuck Labs
Investment portfolio details for Shattuck Labs
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Shattuck Labs
Detailed financials for Shattuck Labs
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Shattuck Labs Comparisons
Peer comparison for Shattuck Labs
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Shattuck Labs
Shattuck Labs operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ALX Oncology, TScan Therapeutics, Lyell Immunopharma, Alpine Immune Sciences and Alector, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ALX Oncology is focused on advancing cancer treatment therapies.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Antibody drugs for cancer treatment are developed.
|
Detailed competitors of Shattuck Labs
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Shattuck Labs
Complete news archive for Shattuck Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shattuck Labs
Shattuck Labs was founded in 2016.
Shattuck Labs is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Shattuck Labs is a funded company, having raised a total of $165.4M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Shattuck Labs is 44.
Annual revenue of Shattuck Labs is $5.72M as on Dec 31, 2024.
Shattuck Labs was founded in 2016 and is headquartered in Austin, United States. The company operates in the biotechnology sector, focusing on oncology and immunology. Its core platform, known as ARC (Agonist Redirected Checkpoints), involves bispecific biologics designed to block checkpoint molecules in cancer while stimulating TNF superfamily costimulatory receptors on T cells and innate immune cells. This approach is applied to various checkpoint targets under clinical development.
Shattuck Labs's top competitors include Alector, Hummingbird Bioscience and Lyell Immunopharma.
Shattuck Labs offers SL-325.
Yes, Shattuck Labs is publicly traded on NASDAQ under the ticker symbol STTK.
Shattuck Labs has 10 investors. Key investors include Fidelity Investments, Orbimed, Janus Henderson Investors, Piper Sandler, and Redmile Group.
The ticker symbol of Shattuck Labs is STTK on NASDAQ.